Pharmacological advances in Candida auris : emerging antifungal mechanisms and next-generation therapeutic strategies
Journal of Enzyme Inhibition and Medicinal Chemistry · 31.12.2026 · 41 (1)
DOI: 10.1080/14756366.2026.2660982 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, online erschienen am 20.07.2026. Verfasst von Shuaibu Abdullahi Hudu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Research, Northern Border University, Arar, Saudi Arabia. Hauptthemen laut MEDLINE: Antifungal Agents, Candida auris. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Northern Border University.
Abstract (Originalsprache)
Candida auris is a major public health concern worldwide due to its efficient transmission, environmental persistence, and broad resistance to approved antifungal classes. This review consolidates recent pharmacological developments in this regard, focusing on mechanistic insights and late-stage therapeutics. Novel agents demonstrate activity against multidrug- and pan-resistant isolates via distinct mechanisms of action and enhanced specific binding to CYP51. Repositioned drugs, host-defense peptides, and quorum-sensing modulators also expand the treatable spectrum, particularly for biofilm-associated and device-related infections. Concurrently, artificial intelligence (AI)-guided discovery, nanocarrier-enabled delivery, and multi-omics profiling are greatly accelerating target identification and enhancing the drug metabolism of small-molecule fragments. The emerging combined approaches mark a transition towards mechanism-based antifungal development to combat the increasing clinical burden posed by C. auris. Ongoing integration of precision diagnostics, pharmacodynamic optimization, and novel discovery platforms will be key to translating these advances into durable, real-world therapeutic solutions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Health Research, Northern Border University, Arar, Saudi Arabia.
- Department of Microbiology, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
- Department of Basic and Clinical Medical Sciences, Faculty of Dentistry, Zarqa University, Zarqa, Jordan.
- Department of Microbiology, Faculty of Medicine, Zagazig University, Zagazig, Al-Sharqia Governorate, Egypt.
- Department of Pharmacology, Faculty of Basic Medical Sciences, Sa'adu Zungur University, Bauchi State, Itas Gadau, Nigeria.
- Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria.
ORCID-Profile: Shuaibu Abdullahi Hudu, Najlaa Saadi, Emad A Morad, Albashir Tahir, Abdulgafar Olayiwola Jimoh
Förderung
- Northern Border University
Zitieren
APA
Hudu, S. A., Saadi, N., Morad, E. A., Tahir, A., & Jimoh, A. O. (2026). Pharmacological advances in Candida auris : emerging antifungal mechanisms and next-generation therapeutic strategies. Journal of Enzyme Inhibition and Medicinal Chemistry, 41(1). https://doi.org/10.1080/14756366.2026.2660982
Vancouver
Hudu SA, Saadi N, Morad EA, Tahir A, Jimoh AO. Pharmacological advances in Candida auris : emerging antifungal mechanisms and next-generation therapeutic strategies. Journal of Enzyme Inhibition and Medicinal Chemistry. 2026;41(1). doi:10.1080/14756366.2026.2660982
BibTeX
@article{Hudu2026,
author = {Hudu, Shuaibu Abdullahi and Saadi, Najlaa and Morad, Emad A and Tahir, Albashir and Jimoh, Abdulgafar Olayiwola},
title = {Pharmacological advances in Candida auris : emerging antifungal mechanisms and next-generation therapeutic strategies},
journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
year = {2026},
volume = {41},
number = {1},
doi = {10.1080/14756366.2026.2660982}
}
EUVIMED